These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25654374)

  • 1. LDA-SVM-based EGFR mutation model for NSCLC brain metastases: an observational study.
    Hu N; Wang G; Wu YH; Chen SF; Liu GD; Chen C; Wang D; He ZS; Yang XQ; He Y; Xiao HL; Huang DD; Xiong KL; Wu Y; Huang M; Yang ZZ
    Medicine (Baltimore); 2015 Feb; 94(5):e375. PubMed ID: 25654374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
    BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.
    Gow CH; Chang YL; Hsu YC; Tsai MF; Wu CT; Yu CJ; Yang CH; Lee YC; Yang PC; Shih JY
    Ann Oncol; 2009 Apr; 20(4):696-702. PubMed ID: 19088172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
    Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
    J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors.
    Yun PJ; Wang GC; Chen YY; Wu TH; Huang HK; Lee SC; Chang H; Huang TW
    PLoS One; 2019; 14(5):e0215923. PubMed ID: 31048854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting EGFR mutation status by a deep learning approach in patients with non-small cell lung cancer brain metastases.
    Haim O; Abramov S; Shofty B; Fanizzi C; DiMeco F; Avisdris N; Ram Z; Artzi M; Grossman R
    J Neurooncol; 2022 Mar; 157(1):63-69. PubMed ID: 35119589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR mutation status in brain metastases of non-small cell lung carcinoma.
    Burel-Vandenbos F; Ambrosetti D; Coutts M; Pedeutour F
    J Neurooncol; 2013 Jan; 111(1):1-10. PubMed ID: 23086434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
    Liu K; Jiang G; Zhang A; Li Z; Jia J
    BMC Cancer; 2020 Jan; 20(1):76. PubMed ID: 32000711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.
    Yang WC; Xiao F; Shih JY; Ho CC; Chen YF; Tseng HM; Chen KY; Liao WY; Yu CJ; Yang JC; Kuo SH; Cheng JC; Yang PC; Hsu FM
    Radiother Oncol; 2018 Feb; 126(2):368-374. PubMed ID: 29111173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological features and epidermal growth factor receptor mutations associated with epithelial-mesenchymal transition in non-small cell lung cancer.
    Deng QF; Zhou CC; Su CX
    Respirology; 2009 Apr; 14(3):371-6. PubMed ID: 19353773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC.
    Fan Y; Wang X; Dong Y; Cui E; Wang H; Sun X; Su J; Luo Y; Yu T; Jiang X
    Eur Radiol; 2023 Nov; 33(11):7902-7912. PubMed ID: 37142868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
    Kim M; Suh CH; Lee SM; Park JE; Kim HC; Kim SO; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
    AJR Am J Roentgenol; 2021 Nov; 217(5):1184-1193. PubMed ID: 34037408
    [No Abstract]   [Full Text] [Related]  

  • 14. Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC.
    Wang BX; Ou W; Mao XY; Liu Z; Wu HQ; Wang SY
    Clin Neurol Neurosurg; 2017 Sep; 160():96-100. PubMed ID: 28704781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
    Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutation status on brain metastases from non-small cell lung cancer.
    Hsu F; De Caluwe A; Anderson D; Nichol A; Toriumi T; Ho C
    Lung Cancer; 2016 Jun; 96():101-7. PubMed ID: 27133758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
    Zhang Y; Wang Q; Han ZG; Shan L
    Asian Pac J Cancer Prev; 2013; 14(5):2879-83. PubMed ID: 23803047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
    Zhang C; Wei B; Li P; Yang K; Wang Z; Ma J; Guo Y
    PLoS One; 2017; 12(3):e0173524. PubMed ID: 28333951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a model to predict tyrosine kinase inhibitor-sensitive EGFR mutations of non-small cell lung cancer based on multi-institutional data.
    Chang H; Liu YB; Yi W; Lu JB; Zhang JX
    Thorac Cancer; 2018 Dec; 9(12):1680-1686. PubMed ID: 30281214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.